Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10732215 | 0.71 | CACNA2D1 (0.33) | — | |
| SCHEMBL17876978 | 0.69 | — | — | |
| SCHEMBL364348 | 0.67 | — | — | |
| SCHEMBL17118654 | 0.67 | — | — | |
| SCHEMBL17876976 | 0.67 | — | — | |
| SCHEMBL18740885 | 0.64 | — | — | |
| SCHEMBL20151688 | 0.64 | — | — | |
| SCHEMBL18740886 | 0.64 | — | — | |
| SCHEMBL20595578 | 0.62 | APLNR (0.32) | APLNR | |
| SCHEMBL29231157 | 0.62 | APLNR (0.32) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114507387-A | Low-smoke halogen-free flame-retardant bunched cable and preparation method thereof | 浙江驰鹰电线电缆有限公司 | 2022-05-17 | — | — | CN | claimed |
| EP-4741399-A1 | LINCOSAMIDE ANTIBIOTICS AND USES THEREOF | President And Fellows Of Harvard College (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12534453-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| EP-3664799-B1 | LINCOSAMIDE ANTIBIOTICS AND USES THEREOF | HARVARD COLLEGE (US) | 2025-10-01 | — | — | EP | disclosed |
| US-20240246939-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2024-07-25 | — | — | US | disclosed |
| EP-4308095-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11767341-B2 | Lincosamide antibiotics and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767341-B2 | Lincosamide antibiotics and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230104740-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2023-04-06 | — | — | US | disclosed |
| EP-3664799-A1 | LINCOSAMIDE ANTIBIOTICS AND USES THEREOF | President And Fellows Of Harvard College (US) | 2020-06-17 | — | — | EP | disclosed |
| WO-2019032936-A1 | LINCONSAMIDE ANTIBIOTICS AND USES THEREOF | PRESIDENT ADN FELLOWS OF HARVARD COLLEGE (US) | 2019-02-14 | — | — | WO | disclosed |
| WO-2019032956-A1 | LINCOSAMIDE ANTIBIOTICS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-02-14 | — | — | WO | disclosed |
| WO-2019032941-A1 | LINCOSAMIDE ANTIBIOTICS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-02-14 | — | — | WO | disclosed |
| WO-2018216822-A1 | NOVEL IMIDAZOLE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2018-11-29 | — | — | WO | disclosed |
| US-9982005-B2 | Macrolides and methods of their preparation and use | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-05-29 | — | — | US | disclosed |
| EP-1019407-B1 | METALLO-PORPHYRINS | QINETIQ LTD (GB) | 2003-08-20 | — | — | EP | disclosed |
| US-6235895-B1 | MONOMERIC OR OLIGOMERIC METALLO-PORPHYRIN DERIVATIVES HAVING MESO-ALKYNYL SUBSTITUENTS. | THE SECRETARY OF STATE FOR DEFENCE (GB) | 2001-05-22 | — | — | US | disclosed |
| EP-1019407-A1 | METALLO-PORPHYRINS | QinetiQ Limited (GB) | 2000-07-19 | — | — | EP | disclosed |
| WO-1998005665-A1 | METALLO-PORPHYRINS | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767341-B2 | Lincosamide antibiotics and uses thereof | LNPEP, LCLAT1, NPEPPS | APLNR 1061/4885 |
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS2, GYS1, PYGL | APLNR 4744/4885 |
| US-20230104740-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | GYS2, GYS1, PYGL | APLNR 4744/4885 |
| US-12534453-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS1, GYS2, GBA1 | APLNR 4272/4885 |
| US-20240246939-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | GYS2, GYS1, PYGL | APLNR 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.